Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445491 | 0.83 | CFTR (0.77) | CFTR | |
| SCHEMBL19879834 | 0.83 | CFTR (0.71) | CFTR | |
| SCHEMBL20086291 | 0.82 | CFTR (0.70) | CFTR | |
| SCHEMBL16445388 | 0.81 | CFTR (0.68) | CFTR | |
| SCHEMBL16445679 | 0.81 | CFTR (1.00) | CFTR | |
| SCHEMBL16450584 | 0.80 | CFTR (0.75) | CFTR | |
| SCHEMBL16445381 | 0.80 | CFTR (0.67) | CFTR | |
| SCHEMBL16445597 | 0.80 | CFTR (0.67) | CFTR | |
| SCHEMBL16450537 | 0.80 | CFTR (0.71) | CFTR | |
| SCHEMBL16450560 | 0.80 | CFTR (0.79) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | claimed |
| US-12583893-B2 | Use of esculentin and its derivatives for use in the treatment of cystic fibrosis | UNIVERSITÀ DEGLI STUDI DI ROMA LA SAPIENZA (IT) | 2026-03-24 | — | — | US | claimed |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| EP-4045074-B1 | USE OF ESCULENTIN AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2025-09-17 | — | — | EP | claimed |
| CN-119947720-A | Methods of treating cystic fibrosis | 弗特克斯药品有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-4525858-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2025052391-A1 | ANTISENSE OLIGONUCLEOTIDES TARGETING THE CFTR 3849+10 KILOBASE (KB) C->T SPLICING MUTATION | SPLISENSE LTD. (IL) | 2025-03-13 | — | — | WO | claimed |
| US-20250049838-A1 | Antisense Compounds Targeting Genes Associated with Cystic Fibrosis | UNIV ROSALIND FRANKLIN MEDICINE & SCIENCE (US) | 2025-02-13 | — | — | US | claimed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | claimed |
| CN-117987468-A | Application of transgenic zebra fish in preparation of acute myelogenous leukemia animal model | 华南理工大学 | 2024-05-07 | — | — | CN | claimed |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | claimed |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | GALAPAGOS SASU (FR) | 2018-04-19 | — | — | US | claimed |
| US-9895347-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-02-20 | — | — | US | claimed |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | claimed |
| EP-3030568-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | Galapagos NV (BE) | 2016-06-15 | — | — | EP | claimed |
| US-9351955-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-05-31 | — | — | US | claimed |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | claimed |
| US-9133210-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2015-09-15 | — | — | US | claimed |
| WO-2015018823-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2015-02-12 | — | — | WO | claimed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583893-B2 | Use of esculentin and its derivatives for use in the treatment of cystic fibrosis | CFTR, SCNN1G, SCNN1B | CFTR 1/4885 |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SLC26A3 | CFTR 1/4885 |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | CFTR 1/4885 |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CFTR 1/4885 |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.